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Objective: The aim of this study is to evaluate the prognostic significance of intraoperative
peritoneal lavage cytology (PLC) in pancreatic invasive ductal adenocarcinoma.
Methods: Intraoperative PLC was evaluated in 162 patients with resectable pancre-
atic invasive ductal adenocarcinoma. The results were analyzed for correlations with
clinicopathological parameters and/or prognoses.
Results: In the 162 cases of resectable pancreatic ductal adenocarcinoma, 18 (11%),
141 (87%), and 3 (2%) were positive, negative, and equivocal for intraoperative
PLC, respectively. Intraoperative PLC positivity was associated with older patients
(over 65 years), large tumor size (over 35mm), tumor location in the body/tail of
the pancreas, and distant metastasis. Univariate analysis showed that larger tumor
sizes (35mm, P=0.001), lymph node metastases (P=0.005), distant metastasis
(P=0.004), advanced stage (stage IIB or III, P=0.006), advanced tumor histologi-
cal grade (G3, P<0.001), or positive intraoperative PLC (P=0.002) are associated
with a shorter survival. Multivariate analysis revealed that larger tumor sizes (35mm,
P=0.026), lymph node metastasis (P=0.021), advanced tumor histological grade (G3,
P<0.001), and positive intraoperative PLC (P=0.002) were independent prognostic
factors.
Conclusion: Intraoperative PLC is an independent prognostic factor for resectable
pancreatic invasive ductal adenocarcinoma.
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Introduction
Pancreatic ductal adenocarcinoma is the most common pan-
creatic neoplasm, and is highly aggressive and malignant with
a very low-survival rate. Several factors, such as large tumor
size, retroperitoneal invasion, location of the tumor in the body
or tail of the pancreas, and lymph node metastasis, are corre-
lated with poor prognosis (1). Ascites or peritoneal lavage fluids
are occasionally analyzed in patients of several cancer types to
evaluate the peritoneal dissemination of tumor cells. In ovar-
ian and fallopian tube cancers, the detection of tumor cells in
ascites or peritoneal lavages is considered a negative prognos-
tic factor, and peritoneal cytology was adopted as one of the
factors determining the stage of the tumor by the International
Federation of Gynecology and Obstetrics as well as the Union
for International Cancer Control/American Joint Committee on
Cancer (UICC/AJCC) classification system (2–4). In pancreatic
ductal adenocarcinoma, the incidence of positive peritoneal cytol-
ogy was 5–30% in resectable cases (5–14) and 20–57% in unre-
sectable cases (6, 8, 9, 11, 15). However, the prognostic sig-
nificance of positive peritoneal cytology has been controversial
for pancreatic ductal adenocarcinoma. Some studies reported
that positive peritoneal cytology is associated with poor prog-
nosis (5, 6, 8–10, 13–17). In contrast, other studies reported
that peritoneal cytology findings do not influence the patients’
prognosis (6–8, 11, 12, 18).
In this study, we retrospectively analyzed the relationship
between intraoperative peritoneal lavage cytology (PLC) out-
comes, clinicopathological parameters, and patient survival in
resectable pancreatic ductal adenocarcinoma cases treated at
Tokai University Hospital.
Materials and Methods
Cases
We retrospectively analyzed 162 consecutive cases of surgically
resected, conventional pancreatic ductal adenocarcinoma with
intraoperative PLC examination treated between 2006 and 2013
at Tokai University Hospital. All cases were diagnosed based on
routine histological examination. We excluded cases of special
histological types, such as adenosquamous carcinoma, mucinous
carcinoma, undifferentiated carcinoma, and intraductal papillary
mucinous neoplasms with invasion, as well as cases that had
undergone preoperative chemotherapy. Tumor resectability was
evaluated with computed tomography and at laparotomy. Lesions
eligible for resection included those without distant metastases
and those with or without involvement of the portal or superior
mesenteric vein as long as resection and reconstruction mar-
gins were deemed safe. Furthermore, tumors with gastroduodenal
artery encasement up to the hepatic artery, with either short
segment encasement or direct abutment to the hepatic artery,
were deemed resectable, as were lesions with no extensions to the
celiac axis and tumors encasing the superiormesenteric artery in a
manner not exceeding 180° of the circumference of the vessel wall
(19). pT-stage, pN-stage, and tumor grade (G) were categorized
according to the UICC/AJCC classification (3, 4). After laparo-
tomy, the Douglas fossa was washed with 200–300mL of saline,
and 10mL of peritoneal ascites was aspirated using a syringe.
The collected peritoneal lavage fluid was centrifuged for 10min
at 600 g. After discarding the supernatant, precipitated cellular
components were smeared onto glass slides, fixed in 95% ethanol,
and subjected to Papanicolaou staining and/or were dried and
subjected to Giemsa staining. Cytological results were classified
as negative, positive, or equivocal. The clinical data were collected
from individual patient records; patients’ clinicopathological fea-
tures are summarized in Table 1. This study was approved by
TABLE 1 | The clinicopathological features.
Total number of cases 162
Mean age, year (SD) 67.2 (8.6)
Sex, no. (%)
Male 77 (47)
Female 85 (53)
Mean size of tumor, cm (SD) 36.2 (16.6)
Local invasion: pT, no. (%)
pT1 7 (4)
pT2 2 (1)
pT3 153 (95)
pT4 0
Lymph node metastasis: pN, no. (%)
pN0 75 (46)
pN1 87 (54)
Distant metastasis: pM, no. (%)
pM0 156 (96)
pM1 6 (4)
Stage, no. (%)
IA 6 (4)
IB 2 (1)
IIA 67 (41)
IIB 81 (50)
III 0
IV 6 (4)
Perineural invasion, no. (%)
Negative 10 (6)
Positive 152 (94)
Lymphatic involvement, no. (%)
Negative 14 (9)
Positive 148 (91)
Venous involvement, no. (%)
Negative 8 (5)
Positive 154 (95)
Tumor site, no. (%)
Head 107 (66)
Body to tail 55 (34)
Tumor grade, no. (%)
G1 61 (38)
G2 90 (55)
G3 11 (7)
EUS-FNA cytology/biopsy
No 156 (96)
Yes 6 (4)
Intraoperative peritoneal cytology, no. (%)
Negative 141 (87)
Positive 18 (11)
Equivocal 3 (2)
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration.
Frontiers in Oncology | www.frontiersin.org August 2015 | Volume 5 | Article 1822
Hirabayashi et al. Peritoneal cytology of pancreatic carcinoma
the Research Ethics Committee of Tokai University School of
Medicine (No. 14R116).
Statistical Analysis
All statistical analyseswere performedusing SPSS version 19 (IBM
Japan, Tokyo, Japan). For univariate analysis, Fisher’s exact test or
Pearson’s chi-squared test was used to determine the relationship
between clinicopathological features andPLC results.Multivariate
analysis between clinicopathological features and PLC results was
performed with logistic regression. Life-table probabilities for the
overall survival were calculated using the Kaplan–Meier method,
and the differences in survival between the subgroups were com-
pared with the log-rank test. The Cox proportional hazard model
was used to calculate the univariate andmultivariate hazard ratios.
A P-value of<0.05 was considered significant.
Results
Results of Intraoperative PLC
Of 162 cases of resectable pancreatic ductal adenocarcinoma, 141
(87%) were negative for intraoperative PLC. Eighteen cases (11%)
were positive, while three cases (2%) were equivocal (Table 1).
Correlation Between Clinicopathological
Parameters and PLC
The correlation between PLC results and clinicopathological
parameters was analyzed (Table 2). Of 159 cases examined after
excluding 3 patients with equivocal cytology results, positive PLC
was associated with tumor sizes 35mm or larger (P= 0.01), ages
65 years and older (P= 0.01), tumor location in the body/tail of
the pancreas (P= 0.047), and the occurrence of distant metastasis
(P= 0.002).
Survival Analysis
Univariate analysis of overall survival in all pancreatic ductal
adenocarcinoma patients revealed that cases significantly asso-
ciated with shorter survival included those with larger tumor
sizes (35mm, P= 0.001), lymph node metastases (P= 0.005),
distant metastasis (P= 0.004), advanced stage (stage IIB or III,
P= 0.006), advanced tumor histological grade (G3, P< 0.001),
or positive intraoperative PLC (P= 0.002) (Table 3). The median
overall survival of patients with positive intraoperative PLC was
significantly shorter than that of patients with negative PLC (10
vs. 27months; P= 0.001) (Figure 1).
Multivariate analysis indicated that larger tumor sizes
(35mm, P= 0.026), lymph node metastasis (P= 0.021),
advanced tumor histological grade (G3, P< 0.001), and positive
intraoperative PLC (P= 0.002) were independent prognostic
factors for resectable pancreatic ductal adenocarcinoma (Table 3).
Discussion
Some studies reported that positive ascitic cytology or PLC are
positively correlated with lymph node metastasis, tumor location
in the body/tail of the pancreas, larger tumor size, vascular inva-
sion, serosal invasion, positive surgical margins, pT-factor, and
advanced stage (5, 7, 9–14, 17). Our study revealed that positive
TABLE 2 | Intraoperative peritoneal cytology and clinicopathological
parameters.
Total number of cases=159 Intraoperative peritoneal
cytology
P-value
Negative
(n=141)
Positive
(n=18)
n (%) n (%)
Age
<65 years (n=51) 50 (98) 1 (2) 0.01
65 years (n=108) 91 (84) 17 (16)
Sex
Male (n= 76) 66 (87) 10 (13) 0.484
Female (n= 83) 75 (90) 8 (10)
Tumor size
<35mm (n= 81) 77 (95) 4 (5) 0.01
35mm (n= 78) 64 (82) 14 (18)
Local invasion: pT
pT1 or 2 (n= 9) 9 (100) 0 0.599
pT3 or 4 (n= 150) 132 (88) 18 (12)
Lymph node metastasis: pN
pN0 (n= 73) 64 (88) 9 (12) 0.712
pN1 (n= 86) 77 (90) 9 (10)
Distant metastasis: pM
pM0 (n= 153) 139 (91) 14 (9) 0.002
pM1 (n= 6) 2 (33) 4 (67)
Stage
Stage I or IIA (n= 73) 64 (88) 9 (12) 0.712
Stage IIB or III or IV (n= 86) 77 (90) 9 (10)
Perineural invasion
Negative (n=10) 10 (100) 0 0.605
Positive (n=149) 131 (88) 18 (12)
Lymphatic involvement
Negative (n=14) 14 (100) 0 0.371
Positive (n=145) 127 (88) 18 (12)
Venous involvement
Negative (n= 7) 7 (100) 0 1
Positive (n= 152) 134 (88) 18 (12)
Tumor site
Head (n= 104) 96 (92) 8 (8) 0.047
Body to tail (n=55) 45 (82) 10 (18)
Tumor grade
G1 or G2 (n=148) 130 (88) 18 (12) 0.615
G3 (n=11) 11 (100) 0
EUS-FNA cytology/biopsy
No (n=153) 137 (90) 16 (10) 0.138
Yes (n= 6) 4 (67) 2 (33)
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration.
intraoperative PLC in resectable pancreatic ductal adenocarci-
noma was associated with larger tumor size (35mm), older age
(65 years), tumor location in the body/tail of the pancreas, and
distant metastasis. Hence, our results are similar to those previ-
ously reported in the literature. As in previous studies, our data
indicated that PLC positivity occurred in resectable pancreatic
ductal adenocarcinomas in advanced stages.
The relationship between positive peritoneal cytology results
and survival of resectable pancreatic ductal adenocarcinoma
patients has been controversial. While several studies con-
cluded that positive peritoneal cytology is associated with poor
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TABLE 3 | Univariate and multivariate analyses regarding the overall
survival.
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age
<65 years (n=53) 1.004
(0.652–1.548)
0.984
65 years (n= 109)
Sex
Male (n=77) 0.898
(0.596–1.353)
0.608
Female (n= 85)
Tumor size
<35mm (n= 82) 2.046
(1.347–3.109)
0.001 1.639
(1.061–2.532)
0.026
35mm (n= 80)
Local invasion: pT
pT1 or 2 (n= 9) 2.483
(0.611–10.096)
0.204
pT3 (n=153)
Lymph node
metastasis: pN
pN0 (n= 75) 1.855
(1.205–2.855)
0.005 1.694
(1.083–2.652)
0.021
pN1 (n= 87)
Distant metastasis:
pM
pM0 (n= 156) 4.481
(1.601–12.541)
0.004 n.s.
pM1 (n= 6)
Stage
Stage I or IIA (n= 75) 1.825
(1.186–2.808)
0.006 n.s.
Stage IIB or III (n=87)
Perineural invasion
Negative (n= 10) 2.04
(0.645–6.454)
0.225
Positive (n=152)
Lymphatic
involvement
Negative (n= 14) 2.305
(0.728–7.296)
0.155
Positive (n=148)
Venous involvement
Negative (n= 8) 3.199
(0.786–13.023)
0.104
Positive (n=154)
Tumor site
Head (n= 107) 0.964
(0.625–1.486)
0.867
Body to tail (n= 55)
Tumor grade
G1 or G2 (n= 151) 3.809
(1.949–7.444)
<0.001 4.411
(2.224–8.750)
<0.001
G3 (n= 11)
Intraoperative
peritoneal cytology
Negative (n= 141) 2.561
(1.414–4.638)
0.002 2.711
(1.464–5.022)
0.002
Positive (n=18)
EUS-FNA
cytology/biopsy
No (n=156) 1.317
(0.181–9.601)
0.786
Yes (n= 6)
HR, hazard ratio; CI, confidence interval; n.s., not significant; EUS-FNA, endoscopic
ultrasound-guided fine needle aspiration.
FIGURE 1 | Kaplan–Meier curve of overall survival in patients of
resectable pancreatic ductal adenocarcinoma according to
intraoperative peritoneal lavage cytology (PLC) status. Survival was
shorter for patients with positive PLC compared to those with negative PLC
(P= 0.001).
survival (5, 6, 9, 10, 13, 14), other studies reported no significant
difference in prognosis between positive and negative peritoneal
cytology (7, 8, 11, 12). Even with multivariate analysis, two con-
flicting results have been reported, one concluding that peritoneal
cytology is an independent prognostic factor (14) and another
stating that it is not (13).
The results of intraoperative PLC may be valuable for deter-
mining the subsequent treatment plan. Surgery for pancreatic
cancer is highly invasive, and postoperative complications some-
times occur as well. Therefore, positive intraoperative PLC results
may lead surgeons to decide to abandon the invasive resection
procedure, particularly in patients who are older or in bad con-
dition. Conversely, positive results in patients who are otherwise
in good condition may prompt the pursuit of more aggressive
postoperative therapy options.
In conclusion, this study revealed that positive intraoperative
PLC in resectable pancreatic ductal adenocarcinoma was asso-
ciated with older age, larger tumor size, tumor location in the
body/tail of the pancreas, and distant metastasis. Patients with
positive intraoperative PLC showed shorter survival times than
those with negative PLC. Our data demonstrate that intraopera-
tive positive PLC in resectable pancreatic ductal adenocarcinoma
is a negative predictor of patient prognosis.
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